10 apr: Tre effektive måder at reducere din formue på
12 apr: Minimalistisk pragtvilla i Sverige
11-04-2012 23:21:00

Quest Diagnostics Names Rusckowski As President, CEO

Relateret indhold

DOW JONES NEWSWIRES

Quest Diagnostics Inc. (DGX) named Royal Philips Electronics NV (PHG, PHIA.AE) executive Stephen Rusckowski as its new president and chief executive, ending a six-month search for a successor to current CEO Surya Mohapatra.

Rusckowski's appointment is effective May 1 and he will also join the company's board. Rusckowski has served as CEO of Philips Healthcare, Royal Philips' largest unit, since 2006.

The management change could mark a new course for the company. Some decisions Quest made under Mohapatra--such as the acquisition of diagnostics company AmeriPath Inc. and an expansion into India--have been criticized by analysts.

Quest, the largest diagnostic-testing company in the U.S. by revenue, had been hurt by a decline in doctor-office visits as consumers have reined in their health-care spending since the recession. Last year, the company unveiled a restructuring initiative to reduce its costs by $500 million over the next three years to help it meet profit targets. In October, the company initiated a search for a replacement for Mohapatra, who held the titles of chairman, president and CEO.

Quest also appointed lead director Daniel C. Stanzione as its new non-executive chairman.

"Steve Rusckowski is uniquely qualified to be chief executive officer of Quest Diagnostics," Stanzione said. "He has built an enviable track record in health care by successfully driving growth, both organically and through disciplined, effective acquisitions. His emphasis on operational excellence has enabled him to deliver consistently impressive results."

In January, Quest reported its fourth-quarter earnings rose 14% as the company saw higher testing revenue and improved margins.

Shares closed at $59.57 Wednesday and were unchanged after hours. The stock is up 2.6% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

(END) Dow Jones Newswires

April 11, 2012 17:21 ET (21:21 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Novo Nordisk/CSO: Vi står i en unik situation

21-06-2018 13:46:41
Novo Nordisk står i en unik position med diabetespillen oral Semaglutid, som i nye studieresultater giver nogle af verdens bedst sælgende diabetesmidler baghjul.Resultaterne fra de pågældende fase 3-studier overstiger forventningerne hos Novo Nordisks forskningsdirektør, Mads Krogsgaard Thomsen, som ser produktet blive verdens bedste tabletbaserede præparat - og dermed også det bedst sælgende. - D..

Ambu/Nordea: Indleder dækningen med "sælg" - 2020-målet for højt - NY

21-06-2018 09:48:10
Nordea indleder dækningen af Ambu-aktien med anbefalingen "sælg". Banken vurderer blandt andet, at Ambus 2020 mål om et salg på 5 mia. kr. er for højt, og at mængden af tidligere opjusteringer har sendt forventningerne op til uholdbare niveauer.Det skriver banken i en analyse.Ambus indtræden i gastrointestinal (GI) endoskopi, hvor Ambu udvikler udstyr til eksempelvis at kunne lave en kikkertunders..

Aktier/tendens: Novo og Chr. Hansen i fokus fra start

21-06-2018 08:19:54
Stærke tendenser for de amerikanske aktier ventes torsdag at sende positive vibrationer ind over aktiemarkederne i Europa, hvor en "dark horse" dog er markedets reaktion på den nedjustering, som den tyske bilgigant Daimler kom med onsdag aften. - Det ser ud til, at vi får lov til at starte lidt bedre op, end man ellers kan frygte, når der er så meget usikkerhed derude. En af de ting, som bliver sp..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Novo og Chr. Hansen i fokus fra start
2
Novo/Sydbank: Flotte data kan sikre høj pris til ny diabetespille - NY
3
Onsdagens aktier: Rekord-Ambu satte C25 til vægs
4
Novo Nordisk/CSO: Vi står i en unik situation
5
Novo/Jefferies: Spår stadig milliardsalg af oral Semaglutid

Relaterede aktiekurser

Philips KON 36,00 -0,2% Fald i aktiekurs
Koninklijke Philips N.V... 41,79 0,0% Aktiekurs uændret
Quest Diagnostics Incorp.. 110,65 -0,1% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. juni 2018 16:27:26
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180619.1 - EUROWEB3 - 2018-06-21 16:27:26 - 2018-06-21 16:27:26 - 1 - Website: OKAY